What is the price target for TPST stock?
7 analysts have analysed TPST and the average price target is 11.22 USD. This implies a price increase of 638.16% is expected in the next year compared to the current price of 1.52.
TEMPEST THERAPEUTICS INC (TPST) Forecast, Price Target & Analyst Ratings
NASDAQ:TPST • US87978U2078
Current stock price
1.52 USD
-0.21 (-12.14%)
At close:
1.59 USD
+0.07 (+4.61%)
Pre-Market:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TEMPEST THERAPEUTICS INC (TPST).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 11, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.63
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$11.22
Upside
+ 638.16%
From current price of $1.52 to mean target of $11.22, Based on 7 analyst forecasts
Low
$11.11
Median
$11.22
High
$11.55
Price Target Revisions
1 Month
0.00%
3 Months
22.22%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for TPST. The average price target is 11.22 USD. This implies a price increase of 638.16% is expected in the next year compared to the current price of 1.52.
The average price target has been revised upward by 22.22% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.86%
TPST was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about TPST.
In the previous month the buy percentage consensus was at a similar level.
TPST was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-22 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-04-10 | ScotiaBank | Downgrade | Sector Outperform -> Sector Perform |
| 2025-04-10 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-03-28 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2025-03-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-21 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-06-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-14 | ScotiaBank | Initiate | Sector Outperform |
| 2024-03-13 | ScotiaBank | Initiate | Sector Outperform |
| 2024-03-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-02-08 | Jefferies | Initiate | Buy |
| 2023-10-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-06-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-28 | Ladenburg Thalmann | Maintains | Buy |
| 2023-03-23 | Piper Sandler | Maintains | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 11, 2026
- Period
- Q4 / 2025
- EPS Estimate
- -$0.63
- Revenue Estimate
- Revenue Q2Q
- N/A
- EPS Q2Q
- 84.31%
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
82.39%
Next Earnings Summary
TPST is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.63 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2025 - 2032
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 280K | 650K 132.14% | 300K -53.85% | 33.997K -100.00% | 3.774M | -100.00% | 48.756M | 119.03M 144.13% | 228.28M 91.78% | ||||||||||
| EBITDA YoY % growth | -70.71M | -73.37M -3.76% | -44.93M 38.76% | N/A 40.26% | -46.816M -68.78% | -36.555M 20.93% | -28.356M 25.68% | -36.72M -27.72% | -30.192M 15.36% | -36.516M -44.69% | -26.112M 37.29% | -28.05M -7.42% | -32.232M -14.91% | -98.328M -205.06% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -72M | -75.61M -5.01% | -46.58M 38.39% | -32.667M 42.31% | -46.064M -68.96% | -36.223M 20.77% | -28.374M 24.97% | -35.979M -28.34% | -29.366M 15.83% | -38.07M -44.14% | -26.112M 37.87% | -28.05M -7.42% | -32.232M -14.91% | -98.328M -205.06% | -18.87M 80.81% | 24.684M 230.81% | 87.516M 254.55% | 185.33M 111.77% | |
| Operating Margin | -25,714.29% | -11,632.31% | -15,526.67% | -96,089.62% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -2,605.41% | N/A | 50.63% | 73.52% | 81.19% | |
| EPS YoY % growth | -7,926.75 | -7,166.25 9.59% | -4,065.75 43.27% | -495.26 87.82% | -633.87 -28.36% | -373.93 40.49% | -85.04 43.09% | -43.12 80.31% | -25.66 40.18% | -17.85 23.08% | -6.22 68.09% | -2.82 54.75% | -2.33 17.39% | -16.21 -596.93% | -4.75 70.67% | 5.19 209.23% | 16.77 222.99% | 31.76 89.42% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.63 84.31% | -3.71 -17.49% | -4.11 -98.58% | -4.11 -420.33% | -4.51 -612.90% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -3.162M 76.63% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -12.24M 12.06% | -13.26M -21.25% | -14.535M -82.46% | -14.79M -311.18% | -16.065M -31.25% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
23.44%
EPS Next 5 Year
11.92%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
4.87%
EBIT Next 5 Year
-26.77%
TEMPEST THERAPEUTICS INC / TPST Forecast FAQ
When does TEMPEST THERAPEUTICS INC (TPST) report earnings?
TEMPEST THERAPEUTICS INC (TPST) will report earnings on 2026-05-11, after the market close.
Can you provide the consensus estimates for TEMPEST THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of TEMPEST THERAPEUTICS INC (TPST) is -0.63 USD and the consensus revenue estimate is 0 USD.